Insider Buying: Dicerna Pharmaceuticals Director Acquires 200,000 Shares of Stock (DRNA)
Dicerna Pharmaceuticals (NASDAQ:DRNA) Director Stephen J. Hoffman bought 200,000 shares of the stock in a transaction that occurred on Tuesday, February 4th. The stock was purchased at an average cost of $15.00 per share, with a total value of $3,000,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Dicerna Pharmaceuticals (NASDAQ:DRNA) traded up 10.51% during mid-day trading on Wednesday, hitting $33.55. The stock had a trading volume of 265,943 shares. Dicerna Pharmaceuticals has a 52 week low of $29.00 and a 52 week high of $44.95. The stock has a 50-day moving average of $34.59 and a 200-day moving average of $34.59. The company’s market cap is $557.8 million.
Dicerna Pharmaceuticals, Inc is a biopharmaceutical company. The Company focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.